I-Mab | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (11)

View All

Latest Posts

About This Stock More About This Stock
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
Article By: ChinaBio® Today
Saturday, June 8, 2024 2:20 PM EDT
Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent BioPharma.
In this article: SMMT, IMAB, GNNSF, GPCR, ASPHF, AVBP, AKESF Also: AZN, BMY
Read
Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million
Article By: ChinaBio® Today
Sunday, February 11, 2024 12:40 PM EDT
I-Mab will become a completely US-based company, divesting itself of I-Mab Biopharma (Hangzhou), an unconsolidated affiliate. I-Mab Hangzhou will acquire rights to I-Mab’s drug assets in Greater China for $80 million.
In this article: BAYRY, TRIB, IMAB, IVBXF, ESAIY
Read
Week In Review: Two China Biopharmas Announce Billion Dollar Deals
Article By: ChinaBio® Today
Saturday, October 14, 2023 12:59 PM EDT
MediLink Therapeutics out-licensed global rights for its antibody-drug conjugate candidate to BioNTech in a $1.1 billion agreement. Meanwhile, BioMap formed a collaboration with Sanofi in a deal with potential value of more than $1 billion.
In this article: IMAB, KNTPF, ASPHF, SNY, BNTX Also: AZN, GSK
Read
Week In Review: Adlai Nortye Stages $97.5 Million US IPO On Nasdaq
Article By: ChinaBio® Today
Saturday, September 30, 2023 2:54 PM EDT
While ANL's IPO dropped more than 25% on its first day, netting just under $60M, private placement made up the difference. Plus: Deals, financings, trials and approvals.
In this article: IMAB, ANL, ABBV, GRCL
Read
Week In Review: Sorrento Acquires ACEA In $488 Million Deal Between Two San Diego-China Oncology Biopharmas
Article By: ChinaBio® Today
Saturday, April 10, 2021 12:55 PM EDT
Sorrento Therapeutics will acquire ACEA Therapeutics in a deal worth up to $488 million. Both companies develop novel cancer drugs, both are headquartered in San Diego and both have operations in China. 
In this article: SRNE, HCM, BGNE, IMAB
Read
All Posts

Latest Tweets for $IMAB

No tweets yet!

PARTNER HEADLINES